[23rd Congress of the European Society for Medical Oncology, 6-10 November 1998, Athens, Greece].
Foggi
P
P
Divisione di Oncologia Medica II, Istituto Regina Elena per lo Studio e la Cura dei Tumori, Roma.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000628:therapy; D002648:Child; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000175:diagnosis / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000628:therapy*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000628:therapy*; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000628:therapy*; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000628:therapy
D000970:Antineoplastic Agents